Study drug for advanced melanoma or lung cancer that kept growing
Part of Cancer clinical trials.
This Phase 1 trial tests KM602, a new study treatment, in people with advanced solid tumors like melanoma or non-small cell lung cancer that have progressed after standard treatments. If you qualify, the goal is to see how the drug works and how safe it is in early research.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma or non-small cell lung cancer (or another solid tumor) that cannot be removed or has spread, and it kept growing after standard care (or standard care isn’t suitable for you).
- Your scans show at least one measurable tumor spot that doctors can track.
- Your general activity level is good (ECOG 0 or 1).
- You’re expected to live at least 12 weeks.
- Your blood, kidney, and liver test results are within allowed limits.
- You have not had certain recent treatments or other research drugs within the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
This Phase 1 trial studies how safe ASKC202 is, what dose is tolerable, and whether it shows early signs of shrinking certain advanced cancers. Depending on your tumor type and prior treatments, ASKC202 may be tested alone or with another drug.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
This trial tests a new drug, MK-6204, in people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This trial tests an investigational treatment called LM303 for people with advanced solid tumors like melanoma, lung cancer, or cervical cancer. It uses your own immune cells (called TILs) to fight the cancer, so you need a tumor large enough for cells to be collected.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.